Market Pulse: Momentum surged as FDA greenlights and retail traders reclaimed control, setting a confident tone ahead of the opening bell.

Key Movers: Vanda’s Nereus approval (Thefly.com) and Novo Nordisk’s defensive positioning in tirzepatide sparked chatter, while retail investors closed out 2025 on a tear (CNBC).

Macro & Politics: Congressional pricing hearings are heating up, threatening to reshape pharma margins just as fresh FDA catalysts come into view.

What’s Next: Keep an eye on today’s FDA docket—new approvals could be the spark small- and mid-caps need.

Market Commentary

Everyone’s ignoring that Washington’s weighty involvement in healthcare pricing is the real catalyst under the biotech boom. Congress is posturing at hearings this week, and if they land even a token rate cap, it’ll knock the wind out of high-flying names like Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market (CNBC) and Vanda jumps 18% to $8.33 after motion sickness FDA approval (Thefly.com). That masked applause for FDA nods overlooks a looming political squeeze—don’t get caught celebrating gains that hinge on policy whims.

It’s wild to see retail armies Retail investors close out one of their best years ever. How they beat Wall Street at their own game (CNBC) chasing short squeezes while Hollywood power brokers scrap over streaming kingdoms Warner Bros. Commits To Rejecting Paramount's Hostile Netflix Takeover Bid (Screen Rant). You’ve got mom-and-pop traders firing up beaten-down stocks as Warner Bros. snubs Paramount’s takeover bid, and both moves signal the same thesis: entrenched giants are vulnerable. Whether it’s a biotech darling or a media titan, markets are telling us that crowd fervor and corporate feuds share a payoff pattern.

Here’s the punch: dial in tomorrow at the pricing hearing, then watch the social-media flows that drove last year’s rally. If legislative pressure spikes or online chatter pivots, you’ll want your stops tight and your alerts set—this year will reward speed and conviction.